

ASX Announcement

22 March 2021

InvestorStream Interview - Presentation

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to provide a copy of the presentation by CEO Derek Thomson for the InvestorStream interview.

The interview is available at:

<https://www.investorstream.com.au/anteotech-release-march>

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

ABOUT ANTEO GROUP – AnteoTech Ltd (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

Follow AnteoTech on Twitter: <https://twitter.com/AnteoTech> or visit www.anteotech.com





AnteoTech

Investor Stream Interview

Life Science Timeline - CE Mark and Beyond

AnteoTech Ltd (ASX:ADO)

Derek Thomson, CEO

22 March 2021

ANTEOTECH INVESTOR HIGHLIGHTS



Diversified investment opportunity with high growth potential in high impact sectors


	Unique, proprietary nano-polymer technology	Proven product AnteoBind in market – Integrated in Ellume Home Test - FDA EUA Proof of concept delivered across Life Science & Energy applications Supported by established suite of IP protection
	Active in Growth markets	Life Science - Lateral Flow Assay (LFA) Market grow to US\$8.7b by 2023 - 7.7% CAGR 2019-2023¹ Energy - Silicon materials market growing by 34% CAGR by 2030¹ in a Lithium battery market growing to +\$100 billion 2030 ²
	Developing solutions in high growth, high impact sectors	Improving Point-Of-Care (POC) testing & assay development in diagnostics, drug development Maximising growth in POC by leveraging diagnostic platform across of new test development, market segment and data opportunities Improving lithium-ion battery energy storage as a result of enhanced silicon integration High potential for future application of technology in other sectors
	Ready to deliver – short to medium term opportunity	~1-3 Months - AnteoTech COVID-19 Antigen Rapid Test in EU and Australian markets ~6-9 Months - COVID-19 & Flu A/B test in late-stage development for US / N. Hemisphere Flu ~6-9 Months - Increasing AnteoBind sale through Ellume ramp up ~12 Months - Sepsis detection test in early pre-clinical development ~12 Months - Commercialisation of AnteoX into battery binder market
	Capital Structure @31/12/20	Revenues: \$0.6 million for H1/FY21 505% growth YoY Cash: \$6.4M Debt: Nil Shares on issue: 1.87 billion

¹ Market Forecast: "Lateral Flow Assay Market by Application, Product, Technique, End User - Global Forecast to 2023" ResearchAndMarkets.com

² Source: Rechargeable Battery Market Main Trends 2017-2030, Avicenne Energy


WHAT SETS ANTEOTECH'S TECHNOLOGY APART

Combining AnteoBind technology with activated Europium achieves the high sensitivity needed for COVID-19



All tests to be developed on this platform use this technology

ANTICIPATED DEVELOPMENT TIMELINE 2021




1. Operon - Manufacturing presence in Spain for COVID-19 ART 2. VIDRL - Victorian Infectious Diseases Reference Laboratory
3. CE Mark is a requirement for EU market, denotes product meets all EU Medical Device Directives


ANTEOBIND & LATERAL FLOW TEST PRINCIPLES



Lateral Flow Test Model



Protein-Particle
Conjugate for detection
in the test is the key
component that impacts
an assay performance



Imaging of an antibody
conjugated, AnteoBind™
activated europium particle

GLOBAL CHALLENGE OF SEPSIS

- Sepsis: preventable, life-threatening condition marked by severe organ dysfunction.
- 2017 studies estimate **49 million** cases and **11 million sepsis-related** deaths worldwide; accounting for 20% of all global deaths
- **Early diagnosis** & timely clinical management are crucial to increase likelihood of survival
- Guidelines recommend antibiotic therapy within **one hour of suspected sepsis**. With each hour antibiotic therapy is delayed, survival **decreases by about 8%**.¹
- Disproportionately affects neonates, pregnant or recently-pregnant women, and people living in low-resource settings. ~85% sepsis cases and deaths occur in these settings.
- Sepsis frequently results from infections acquired in healthcare settings – **1 in 4 cases of sepsis in hospitals** and **1 in 2 cases of sepsis in ICUs** result from healthcare-associated infections.
- World Health Assembly declared combating sepsis a global priority in 2017 and addressing impact will significantly contribute to achieving Sustainable Development Goals on Health

~ 20%
global deaths
due to sepsis

‘Rapid, affordable and appropriate diagnostic tools, particularly for primary and secondary levels of care, are needed to improve sepsis identification, surveillance, prevention and treatment.’

WHO Global Report on Epidemiology and Burden of Sepsis, Sep 2020

Source: World Health Organisation Global Report on Sepsis, September 2020

¹ Early Recognition and Management of Sepsis in Adults: The First Six Hours (Am Fam Physician. 2013 Jul 1;88(1):44-53.)

LEVERAGING CURRENT DEVELOPMENT

Investment in the current test platform could instigate a number of leverage plays that will **accelerate revenue**

Current Tests

- COVID-19
- COVID-19 Flu A&B
- Sepsis

Leverage test development capability to produce future tests including potential for:

- COVID-19 antibody
- Infectious diseases
- Bacterial diseases
- Viral conditions
- Cardiac conditions



Test suite enabled on different reader platforms designed for market segments

- In field testing – military / refugee / care org.
- Mining / oil & gas / remote location medical services
- At home testing
- Low- and middle-income country testing

Quantitative Clinical Decision Support

- Enhanced quantitative detection algorithms
- Leverage patient data banks
- More accurate clinical intervention decision support

